Targets › RAMP1
1 program from 1 company in 2 trials: 2 Phase 1; Neurology; next expected readout Aug 2027.
Accessory protein that interacts with and modulates the function of G protein-coupled receptors including calcitonin gene-related peptide type 1 receptor (CALCRL) and calcitonin receptor (CALCR). Required for the transport of CALCRL to the plasma membrane. (UniProt, O60894)
Open in Phaseline: the race on RAMP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | Zavegepant (PF-07930207) Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist; Calcitonin gene-related peptide type 1 receptor antagonist | RAMP1, CALCRL | Phase 1 | Acute Treatment of Migraine; Migraine | Aug 2027 |
Acute Treatment of Migraine (1) Migraine (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.